Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

BGT

  • Home
  •  
  • BGT



  • Most Read
  • Latest Comments
  • Eco-toxicity findings confirm Bio-Gene pesticide safe for aquatic life
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Eco-toxicity findings confirm Bio-Gene pesticide safe for aquatic life
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Eco-toxicity findings confirm Bio-Gene pesticide safe for aquatic life
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Eco-toxicity findings confirm Bio-Gene pesticide safe for aquatic life
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Eco-toxicity findings confirm Bio-Gene pesticide safe for aquatic life
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Holista Colltech banks on new partners to turn fortunes as food sales struggle
    Holista Colltech banks on new partners to turn fortunes as food sales struggle
    • News

  • Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    • News

  • Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
    Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
    • News

  • Arovella completes development for cell therapy platform, moves to large scale manufacturing
    Arovella completes development for cell therapy platform, moves to large scale manufacturing
    • News

  • Eco-toxicity findings confirm Bio-Gene pesticide safe for aquatic life
    • News

    Eco-toxicity findings confirm Bio-Gene pesticide safe for aquatic life

    Following preliminary eco-toxicity studies on limited aquatic species, agtech developer Bio-Gene Technology (ASX: BGT) has reported favourable results for its flagship next-gen insecticide, Flavocide.  The studies were completed on guppy fish, water fleas and freshwater algae which represented key species of marine life most likely to be impacted by the introduction of pesticide. Following application

    Read More
    Public
  • Leading research body invests in Bio-Gene’s fight against grain pests
    • News

    Leading research body invests in Bio-Gene’s fight against grain pests

    At a time when drought has ravaged Australian farmers, food storage is poised to play a vital role in the nation’s agriculture production which is seeing significant industry investment in Bio-Gene Technology (ASX: BGT) and their grain pest control products.  In the latest round of announcements, Bio-Gene has confirmed the addition of Grains Research and

    Read More
    Public
  • Grain storage pests no match for Bio-Gene after Flavocide trials reach six-month mark
    • News

    Grain storage pests no match for Bio-Gene after Flavocide trials reach six-month mark

    Since the commencement of their program to fight grain storage pests, Agriculture technology company Bio-Gene Technology (ASX: BGT) continues to report strong trial results with current trials reaching the six-month mark and still effectively preventing pest growth.  As the world population continues expanding and higher food storage levels are required, loss of grains and grain-based

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.